肝细胞癌（HCC）是全球第六大常见癌症，也是原发性肝脏肿瘤中排名第一的癌症。近年来，酪氨酸激酶抑制剂（TKI）在单一疗法或与免疫检查点抑制剂（ICIs）联合使用中取得了更大的治疗进展。在过去几年中，靶向治疗受到了极大的关注，特别是在目前的靶向治疗中。 II 期试验。优先考虑的是新型 ICI 和 TKI 的组合，或者针对主要致癌途径的替代突变的组合。由于 TKI 在 HCC 治疗策略中发挥着越来越重要的作用，因此进一步扩大分子检测和获得性耐药监测至关重要。尽管最近实验室和临床研究都取得了进展，但仍需要进一步的研究来面对临床实践的差异。

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the first for primary liver tumors. In recent years greater therapeutic advancement was represented by employment of tyrosine kinase inhibitors (TKIs) either in monotherapy or in combination with immune checkpoint inhibitors (ICIs).Major attention was given to target therapies in the last couple of years, especially in those currently under phase II trials. Priority was given either to combinations of novel ICI and TKIs or those targeting alternative mutations of major carcinogenic pathways.As TKIs are playing a more crucial role in HCC therapeutic strategies, it is fundamental to further expand molecular testing and monitoring of acquired resistances. Despite the recent advancement in both laboratory and clinical studies, further research is necessary to face the discrepancy in clinical practice.